BPC-157 Side Effects

Known side effects

The following side effects have been reported in research studies and user reports for BPC-157:

• Generally well-tolerated across all preclinical species tested — a comprehensive toxicology study (PMID: 32334036) found no adverse effects in mice, rats, rabbits, or dogs at doses up to 20 mg/kg over 6 weeks
• No genetic toxicity, no embryo-fetal toxicity, and no organ damage detected in formal preclinical safety evaluation (PMID: 32334036)
• A 2-person IV safety pilot (PMID: 40131143) reported zero adverse effects at doses of 10mg and 20mg, though the sample size is too small for definitive safety conclusions
• Nausea reported occasionally by users in community forums, particularly during the first few days of use
• Dizziness reported rarely, typically mild and self-resolving
• Headache reported by some users, more common at higher doses
• Injection site redness, mild swelling, or irritation at the subcutaneous injection location
• Anxiety and panic episodes reported by a subset of users in online communities — possibly related to BPC-157's interaction with the dopamine system
• Anhedonia (difficulty experiencing pleasure) reported rarely on forums such as r/peptides — mechanism unclear but may relate to serotonergic modulation
• Fatigue or lethargy reported uncommonly, typically transient
• Gastrointestinal discomfort possible with oral forms, including mild bloating or stomach upset
• Theoretical concern regarding tumor angiogenesis: because BPC-157 promotes blood vessel formation, there is an unresolved question about whether it could support tumor growth in individuals with active cancer
• The Phase I human safety trial (NCT02637284) was completed but results were never published, leaving a transparency gap in the safety literature
• Long-term human safety data does not exist — the vast majority of evidence comes from animal studies lasting 4-8 weeks

Severity and frequency

Limited clinical data is available for BPC-157. Side effect frequency and severity are based on available research and anecdotal reports. More data is needed for definitive safety profiles.

When to seek medical attention

Contact your healthcare provider immediately if you experience:

• Severe or persistent symptoms that do not improve
• Signs of an allergic reaction (rash, swelling, difficulty breathing)
• Severe abdominal pain
• Changes in vision or neurological symptoms
• Any symptom that concerns you

Risk factors

Side effect risk may be higher in certain populations. Discuss your complete medical history with your doctor, including:

• Pre-existing medical conditions
• Current medications (drug interactions)
• Pregnancy or plans to become pregnant
• History of allergic reactions to peptides or similar compounds
• Note: BPC-157 is a research compound without established human safety data from FDA-approved clinical trials

Research references

• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS Journal (2025) [PubMed]
• Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — Alternative Therapies in Health and Medicine (2025) [PubMed]
• Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds — Regulatory Toxicology and Pharmacology (2020) [PubMed]
• Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation — Journal of Molecular Medicine (2017) [PubMed]
• Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth — Journal of Orthopaedic Research (2003) [PubMed]
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — Journal of Applied Physiology (2011) [PubMed]
• Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application — Medical Science Monitor (2010) [PubMed]
• Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation — Bone (1999) [PubMed]
• Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice — Burns (2001) [PubMed]
• Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro — Drug Design, Development and Therapy (2015) [PubMed]
• Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration: a comparative study with dopamine agonists and somatostatin — Life Sciences (1993) [PubMed]
• Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats — Collegium Antropologicum (2005) [PubMed]
• Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway — Scientific Reports (Nature) (2020) [PubMed]
• Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract — Current Pharmaceutical Design (2011) [PubMed]
• Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions — Life Sciences (2011) [PubMed]